192 related articles for article (PubMed ID: 12782585)
1. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
[TBL] [Abstract][Full Text] [Related]
2. GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
Lee Y; Vassilakos A; Feng N; Jin H; Wang M; Xiong K; Wright J; Young A
Int J Oncol; 2006 Feb; 28(2):469-78. PubMed ID: 16391803
[TBL] [Abstract][Full Text] [Related]
3. GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
Vassilakos A; Lee Y; Viau S; Feng N; Jin H; Chai V; Wang M; Avolio T; Wright J; Young A
Int J Oncol; 2009 Jan; 34(1):33-42. PubMed ID: 19082475
[TBL] [Abstract][Full Text] [Related]
4. RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
Avolio TM; Lee Y; Feng N; Xiong K; Jin H; Wang M; Vassilakos A; Wright J; Young A
Anticancer Drugs; 2007 Apr; 18(4):377-88. PubMed ID: 17351390
[TBL] [Abstract][Full Text] [Related]
5. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2.
Ferdinandi ES; Vassilakos A; Lee Y; Lightfoot J; Fitsialos D; Wright JA; Young AH
Cancer Chemother Pharmacol; 2011 Jul; 68(1):193-205. PubMed ID: 20886212
[TBL] [Abstract][Full Text] [Related]
6. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
[TBL] [Abstract][Full Text] [Related]
7. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
9. GTI-2040. Lorus Therapeutics.
Orr RM
Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
[TBL] [Abstract][Full Text] [Related]
10. Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs.
Fan H; Villegas C; Huang A; Wright JA
Cancer Res; 1996 Oct; 56(19):4366-9. PubMed ID: 8813126
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
Hu Y; Cherton-Horvat G; Dragowska V; Baird S; Korneluk RG; Durkin JP; Mayer LD; LaCasse EC
Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
[TBL] [Abstract][Full Text] [Related]
12. GTI-2501. Lorus Therapeutics.
Tu GC; Tu X
Curr Opin Investig Drugs; 2001 Oct; 2(10):1467-70. PubMed ID: 11890367
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
[TBL] [Abstract][Full Text] [Related]
14. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma.
Cao MY; Lee Y; Feng NP; Xiong K; Jin H; Wang M; Vassilakos A; Viau S; Wright JA; Young AH
Clin Cancer Res; 2003 Oct; 9(12):4553-61. PubMed ID: 14555530
[TBL] [Abstract][Full Text] [Related]
16. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
[TBL] [Abstract][Full Text] [Related]
18. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice.
Aharinejad S; Abraham D; Paulus P; Abri H; Hofmann M; Grossschmidt K; Schäfer R; Stanley ER; Hofbauer R
Cancer Res; 2002 Sep; 62(18):5317-24. PubMed ID: 12235002
[TBL] [Abstract][Full Text] [Related]
19. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
